ONXEO/ FR0010095596 /
- - | Chg. - | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
-EUR | - | - Turnover: - |
-Bid Size: - | -Ask Size: - | - | - |
GlobeNewswire
02-28
PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invas...
GlobeNewswire
2021-10-14
Onxeo Further strengthens its Board of Directors with two Seasoned Personalities from the Healthcare...
GlobeNewswire
2021-07-29
Onxeo Announces the Appointment of Dr. Shefali Agarwal as the Company’s Chairwoman of the Board
GlobeNewswire
2021-06-09
Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA™ in combinat...
GlobeNewswire
2021-05-31
Onxeo Announces Formation of Scientific Advisory Committee of Leading Independent Experts
GlobeNewswire
2021-04-21
Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update
GlobeNewswire
2020-11-09
Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study and Positive Interim Results
GlobeNewswire
2020-10-22
Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA™ ...
GlobeNewswire
2020-09-17
Onxeo Reports its Financial Results for the First Half of 2020 and Provides an Update on its Activit...
GlobeNewswire
2020-09-08
Onxeo to Attend Key Investor Conferences and Events in the Second Half of 2020
GlobeNewswire
2020-09-03
Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via...
GlobeNewswire
2020-08-27
Onxeo Reports Publication of Final Results of DRIIV Phase 1 Dose-Escalation Study of AsiDNA™ in Adva...
GlobeNewswire
2020-07-29
Transfer of the Listing of Onxeo Securities From the Euronext Paris Regulated Market (Compartment C)...
GlobeNewswire
2020-06-25
Onxeo Confirms in Preclinical Studies the Profile of OX401, a Potent PARP Agonist with Strong Anti-T...
GlobeNewswire
2020-05-19
Onxeo to Present New Preclinical Data at AACR 2020 Confirming the Ability of AsiDNA™ to Reverse Canc...
GlobeNewswire
2020-04-17
Onxeo Reports Full-Year 2019 Financial Results and Provides Business Update
GlobeNewswire
2020-04-06
Onxeo to Receive $6.6 Million by Granting Additional Exclusive Rights to Belinostat to Acrotech Biop...
GlobeNewswire
2020-02-27
Onxeo to Present Next-Generation PARP inhibitor, OX401, at the European ESMO-TAT Congress 2020